Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-09-09
2008-09-09
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S350000, C530S387300, C424S192100
Reexamination Certificate
active
11075047
ABSTRACT:
The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.
REFERENCES:
patent: 3691016 (1972-09-01), Patel et al.
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4342776 (1982-08-01), Cragoe, Jr. et al.
patent: 4526988 (1985-07-01), Hertel
patent: 4808614 (1989-02-01), Hertel
patent: 4861719 (1989-08-01), Miller
patent: 5004758 (1991-04-01), Boehm et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5223608 (1993-06-01), Chou et al.
patent: 5234784 (1993-08-01), Aslam et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5328688 (1994-07-01), Roizman
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5474982 (1995-12-01), Murray et al.
patent: 5512545 (1996-04-01), Brown et al.
patent: 5585362 (1996-12-01), Wilson et al.
patent: 5620985 (1997-04-01), Jacquesy et al.
patent: 5622856 (1997-04-01), Natsoulis
patent: 5658776 (1997-08-01), Flotte et al.
patent: 5661033 (1997-08-01), Ho et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5686278 (1997-11-01), Williams et al.
patent: 5693509 (1997-12-01), Cotten et al.
patent: 5707618 (1998-01-01), Armentano et al.
patent: 5770414 (1998-06-01), Gage et al.
patent: 5773289 (1998-06-01), Samulski et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5789390 (1998-08-01), Descamps et al.
patent: 5824544 (1998-10-01), Armentano et al.
patent: 5830725 (1998-11-01), Nolan et al.
patent: 5830727 (1998-11-01), Wang et al.
patent: 5834441 (1998-11-01), Philip et al.
patent: 5849571 (1998-12-01), Glorioso et al.
patent: 5851521 (1998-12-01), Branellec et al.
patent: 5856152 (1999-01-01), Wilson et al.
patent: 5863541 (1999-01-01), Samulski et al.
patent: 5879934 (1999-03-01), DeLuca
patent: 5888502 (1999-03-01), Guber et al.
patent: 5952199 (1999-09-01), Davis-Smyth et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6348333 (2002-02-01), Niwa et al.
patent: 6375929 (2002-04-01), Thomas, Jr. et al.
patent: 6383486 (2002-05-01), Davis-Smyth et al.
patent: 6630124 (2003-10-01), Gozes et al.
patent: 6699843 (2004-03-01), Pietras et al.
patent: 6824777 (2004-11-01), Alitalo et al.
patent: 7034105 (2006-04-01), Alitalo et al.
patent: 7070959 (2006-07-01), Papadopoulos et al.
patent: 2002/0103345 (2002-08-01), Zhu
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2002/0164687 (2002-11-01), Eriksson et al.
patent: 2002/0164710 (2002-11-01), Eriksson et al.
patent: 2003/0053989 (2003-03-01), Kovesdi
patent: 2003/0055006 (2003-03-01), Siemeister et al.
patent: 2003/0064053 (2003-04-01), Liu et al.
patent: 2003/0092604 (2003-05-01), Davis-Smyth et al.
patent: 2003/0108545 (2003-06-01), Rockwell et al.
patent: 2003/0113324 (2003-06-01), Alitalo et al.
patent: 2004/0014667 (2004-01-01), Daly et al.
patent: 2004/0208879 (2004-10-01), Alitalo et al.
patent: 2006/0177901 (2006-08-01), Alitalo et al.
patent: 418099 (1991-03-01), None
patent: WO-98/28621 (1998-07-01), None
patent: WO-00/25085 (2000-05-01), None
patent: WO-01/62942 (2001-08-01), None
patent: WO-02/060950 (2002-08-01), None
patent: WO-03/029814 (2003-04-01), None
Achen et al., “Monoclonal Antibodies to Vascular Endothelial Growth Factor-D Block its Interactions with both VEGF Receptor-2 and VEGF Receptor-3,”Eur. J. Biochem., 267:2505-2515 (2000).
Achen et al., “Vascular Endothelial Growth Factor D (VEGF-D) is a Ligang for the Tyrosine Kinases VEGF Receptor 2 (FLK1) and VEGF Receptor 3 (FLT4),”Proc. Natl. Acad. Sci.(USA), 95(2):548-553 (1998).
Baulcombe, “Gene Silencing: RNA Makes RNA Makes No Protein,”Curr. Biol., 9:R599-R601 (1999).
Borg et al., “Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-related Tyrosine Kinase,”Oncogene, 10(5):973-984 (1995).
Bruggemann et al., “Production to Human Antibody Repertoires in Transgenic Mice,”Curr. Opin. Biotechnol., 8:455-458 (1997).
Bruggemann et al., “Strategies for Expressing Human Antibody Repertoires in Transgenic Mice,”Immunol. Today, 17(8):391-397 (1996).
Carter et al., “Toward the Production of Bispecific Antibody Fragments for Clinical Applications,”J. Hematotherapy, 4:463-470 (1995).
Davis-Smyth et al., “The Second Immunoglobulin-like Domain of the VEGF Tyrosine Kinase Receptor Flt-1 Determines Ligang Binding and May Initiate a Signal Transduction Cascase,”EMBO J., 15(18):4919-4927 (1996).
de Azevedo et al., “Molecular Cloning and Expression of a Functional Snake Venom Vascular Endothelium Growth Factor (VEGF) from theBothrops InsularisPit Viper,”J. Biol. Chem., 276:39836-39842 (2001).
De Vries et al., “TheFins-like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science, 255:989-991 (1992).
Egeblad et al., “Cell Death Induced by TNF or Serum Starvation is Independent of ERbB Receptor Signaling in MCF-7 Breast Carcinoma Cells,”Int. J. Cancer, 86:617-625 (2000).
Fairbrother et al., “Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-binding Site,”Biochemistry, 37:17754-17764 (1998).
Ferrara, “Molecular and Biological Properties of Vascular Endothelial Growth Factor,”J. Mol. Med., 77:527-543 (1999).
Fire, “RNA-triggered Gene Silencing,”Trends Genet, 15:358-363 (1999).
Folkman et al., “Long-term Culture of Capillary Endothelial Cells,”Proc. Natl. Acad. Sci.(USA), 76:5217-5221 (1979).
Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,”J. Mol. Biol., 224:487-499 (1992).
Fuh et al., “Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor,”J. Biol. Chem., 273(18):11197-11204 (1998).
Gasmi et al., “Complete Structure of an Increasing Capillary Permeability Protein (ICPP) Purified fromVipera lebetinaVenom,”J. Biol. Chem., 277(33):29992-29998 (2002).
Gasmi et al., “Purification and Characterization of a Growth Factor-like Which Increases Capillary Permeability fromVipera lebetinaVenom,”Biochem. Biophys. Res. Commun., 268:69-72 (2002).
Green et al., “Antigen-specific Human Monoclonal Antibodies from Mice Engineered with Human Ig Heavy and Light Chain YACs,”Nature Genetics, 7:13-21 (1994).
Grimmond et al., “Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor,”Genome Res., 6:124-131 (1996).
Hauser et al., “A Heparin-Binding Form of Placenta Growth Factor (PIGF-2) is Expressed in Human Umbilical Vein Endothelial Cells and in Placenta,”Growth Factors, 9:259-268 (1993).
Hoogenboom, “Designing and Optimizing Library Selection Strategies for Generating High-affinity Antibodies,”TIBTECH, 15:62-70 (1997).
Hughes et al., “Alternative Splicing of the Human VEGFGR-3/FLT4 Gene as a Consequence of an Integrated Human Endogenous Retrovirus,”J. Mol. Evol., 52(2):77-79 (2001).
Hunter, “Genetics: A Touch of Elegance with RNAi,”Curr. Biol., 9:R440-R442 (1999).
Jacobs et al., “Surface Modification for Improved Blood Compatibility,”Artif. Organs, 12:500-501 (1988).
Jones et al., “Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse,”Nature, 321:522-525 (1986).
Joukov et al., “Proteolytic Processing Regulated Receptor Specificity and Activity of VEFG-C,”EMBO J., 16:3898-3911 (1997).
Kaplan et al., “Characterization of a Soluble Vasc
Alitalo Kari
Jeltsch Markku M.
Allen Marianne P
Marshall & Gerstein & Borun LLP
Vegenics Limited
LandOfFree
VEGFR-3 fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VEGFR-3 fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGFR-3 fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3949704